China Medical Technologies, Inc.
China Medical Technologies, Inc. (the "Company") is a China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic ("IVD") products using Enhanced Chemiluminescence ("ECLIA") technology, Fluorescent in situ Hybridization ("FISH") technology and Surface Plasmon Resonance (“SPR”) technology to detect and monitor various diseases and disorders. China Medical Technologies was listed on the Nasdaq Global Select Market on August 10, 2005 and trades under the ticker "CMED". ECLIA is operated through our wholly-owned subsidiary Beijing Yuande Bio-Medical Engineering Co., Ltd. ("Yuande") in China. Yuande was established in 1999 and its headquarters and manufacturing facilities are located in the Beijing Economic-Technological Development Area. The Company was awarded ISO 9001 certification and ISO 13485:2003 certification in 2006.
Our first ECLIA analyzers and reagents were launched in 2004. In light of the Company's extensive research in chemiluminescence technology, we believe we are one of the first China-based companies to successfully develop the products and, more importantly, the first to offer an integrated platform including self-developed analyzers and reagents. We manufacture both the equipment and reagents that detect and monitor various diseases and disorders by analyzing blood through laboratory evaluation. FISH and SPR are operated through our other wholly-owned subsidiary, Beijing GP Medical Technologies, Ltd., which was established in 2006. We acquired our FISH business in March 2007 and launched our FISH-related products in the same year. We believe the FISH products will complement our existing ECLIA diagnostic products by providing proprietary tests for the diagnosis of prenatal and postnatal disorders as well as various cancers that arise from genetic mutations.
Contact Details
Executives
Chairman and CEO
Xiaodong Wu
CFO and Director
Takyung (Sam) Tsang